Study confirms everolimus can overcome trastuzumab resistance in HER-2 positive early breast cancer

(European Society for Medical Oncology) A study that aimed to understand how the cancer drug everolimus helps overcome the resistance breast cancers can develop to trastuzumab showed a statistically non-significant benefit in clinical response rates when everolimus is added to trastuzumab.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news